1. Home
  2. LX vs NMRA Comparison

LX vs NMRA Comparison

Compare LX & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LexinFintech Holdings Ltd.

LX

LexinFintech Holdings Ltd.

HOLD

Current Price

$0.52

Market Cap

102.7M

Sector

Finance

ML Signal

HOLD

Logo Neumora Therapeutics Inc.

NMRA

Neumora Therapeutics Inc.

HOLD

Current Price

$0.32

Market Cap

87.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LX
NMRA
Founded
2013
2019
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
102.7M
87.4M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
LX
NMRA
Price
$0.52
$0.32
Analyst Decision
Buy
Buy
Analyst Count
5
8
Target Price
$2.13
★ $5.33
AVG Volume (30 Days)
843.4K
★ 1.4M
Earning Date
12-01-2026
11-16-2026
Dividend Yield
★ 71.14%
N/A
EPS Growth
N/A
★ 5.23
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.08
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.30
52 Week High
$3.88
$3.65

Technical Indicators

Market Signals
Indicator
LX
NMRA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
LX
NMRA

About LX LexinFintech Holdings Ltd.

LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: